Slide 1: The CORE-NK Platform Phase 1 Clinical Data
For personal use only THE ASX LEADER IN CELL THERAPY THE CORE-NK PLATFORM PHASE 1 CLINICAL DATA MONDAY MARCH 7, 2022
Slide 2: CORE-NK Platform (CHM 0201)
CORE-NK PLATFORM (CHM 0201) Clinically Validated, Off the Shelf, Robust, Enhanced, Natural Killer Cell Platform For personal use only ▪ A universal, off the shelf, natural killer cell platform technology ▪ Developed by Dr. David Wald, a clinical scientist at Case Western Reserve University ▪ Specifi
Slide 3: Positive Phase 1A Clinical Data
CORE-NK Platform Positive Phase 1A Clinical Data For personal use only COMPELLING EFFICACY IN BLOOD DEMONSTRATED CANCERS SAFETY Positive safety profile established with 100% Disease Control Rate (DCR) achieved in no Graft versus Host Disease (GvHD), blood cancer patients (n=3) Cytokine Release Syndr
Slide 4: Phase 1A Trial Design
CORE-NK PLATFORM PHASE 1A TRIAL DESIGN For personal use only The trial was designed to establish the safety of CORE-NK universal donor NK cells while assessing cell expansion, persistence and anti-tumor activity. BLOOD CANCERS PRIMARY OBJECTIVE: Acute Myeloid Leukemia To demonstrate that escalating
Slide 5: Phase 1A Trial Design: Dose Escalation
CORE-NK PLATFORM PHASE 1A TRIAL DESIGN For personal use only PHASE 1 DOSE ESCALATION Dosing: 9 patients : 3 Blood Cancers / 6 Solid Tumors Day - Day Day Day Day 7 0 14 28 100 Initiation of NK Cell NK Cell Disease Disease Lympho- Infusion Infusion Assessment Assessment depletion #1 #2 4.
Slide 6: Phase 1 Study Results: Safety Established Across All Dose Levels
CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS SAFETY ESTABLISHED ACROSS ALL DOSE LEVELS For personal use only NO DOSE LIMITING NO GRAFT VERSUS HOST NO CYTOKINE RELEASE TOXICITIES DISEASE (GVHD) SYNDROME (CRS) NO (DLT’S) All observed events were expected events attributable to the lymphocyte-depleting che
Slide 7: Phase 1 Study Results: Disease Stability
CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS For personal use only 5 OF 9 (56%) PATIENTS EXPERIENCED DISEASE STABILITY INCLUDING ONE COMPLETE REMISSION Cell Dose 10 x 106/kg 25 x 106/kg 50 x 106/kg Patient ID # #1 #4 #5 #7 #8 #12 #13 #14 #15 High-Risk MDS, post- Myeloid Diagnosis MDS/AML Colorectal Colo
Slide 8: 100% Disease Control in Patients with Blood Cancers
CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS 100% DISEASE CONTROL IN PATIENTS WITH BLOOD CANCERS For personal use only Hematological Malignancies Cell Dose 10 x 106/kg 25 x 106/kg 25 x 106/kg Patient ID # Diagnosis #1 MDS/AML #8 High-Risk MDS, #12 Myeloid 100% 66% 1 CRi post-HCT relapse Sarcoma With 15+
Slide 9: Complete Response in High Risk MDS
CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS COMPLETE RESPONSE IN HIGH RISK MDS For personal use only Case Study: Patient ID #8 Complete response with 15+ months ongoing remission DIAGNOSIS: High risk MDS with circulating blasts and high tumor burden HISTORY: Progressive disease with prior allogeneic tr
Slide 10: Disease Control in Heavily Pre-Treated Metastatic Colorectal Patients
CORE-NK (CHM 0201) PHASE 1 STUDY RESULTS1 DISEASE CONTROL IN HEAVILY PRE-TREATED METASTATIC COLORECTAL PATIENTS For personal use only Cell Dose 10 x 106/kg 25 x 106/kg 50 x 106/kg Patient ID # #4 #5 #7 #13 #14 #15 Diagnosis Metastatic Colorectal Multiple Colorectal Lungs Colorectal Multiple Colon Mu
Slide 11: Demonstrated Expansion and Persistence with Universal Donor NK Cells
CORE-NK PLATFORM (CHM 0201) DEMONSTRATED EXPANSION AND PERSISTENCE WITH UNIVERSAL DONOR NK For personal use only CELLS Universal Donor Robust Expansion 28 Day (non-HLA matched) Demonstrated Persistence NK cells (up to 30,000-fold) with no GvHD 10.
Slide 12: Phase 1 Clinical Trial: Overcoming the Challenges of NK Cell Development
CORE-NK PLATFORM PHASE 1 CLINICAL TRIAL: OVERCOMING THE CHALLENGES OF NK CELL DEVELOPMENT For personal use only Established anti-tumor effect with responses in blood cancers THERAPEUTIC EFFECT IN SOLID TUMORS AND BLOOD CANCERS 01 and solid tumors past day 100 and a complete response in High-Risk MDS
Slide 13: Accelerating Multiple Development Paths
CORE-NK PLATFORM (CHM 0201) ACCELERATING MULTIPLE DEVELOPMENT PATHS For personal use only 1. CORE-NK Combination Therapy Rapid development in combination therapy Next Generation CORE-NK Platform 2. Further enhancement with next generation technologies CHM 0201 CORE-NK Platform CAR-NK Products 3. Fas
Slide 14: A Robust and Advanced Cell Therapy Portfolio and Pipeline
A ROBUST AND ADVANCED CELL THERAPY PORTFOLIO AND PIPELINE For personal use only 7 Unique Assets 8 Clinical Programs by 2023 10+ Disease Areas 13.
Slide 15: For personal use only
15 ✓ Innovative & Diversified Portfolio ✓ Broad Therapeutic 7 novel individualized (autologous) T Focus cell and off the shelf (allogeneic) NK Development 10+ types of blood For personal use only cell therapies cancers and solid tumors for extensive commercial opportunity ✓ Extensive Clinical ✓ Earl
Slide 16: Contact Information
For personal use only CONTACT INFORMATION Jennifer Chow Paul Hopper Chief Executive Officer Executive Chairman and Managing Director Cell: +61 406 671 515 Cell: +1 908-723-8387 paulhopper@lifescienceportfolio.com jchow@chimerictherapeutics.com